Researchers have conducted one of the largest eye studies in the world to reveal new insights into retinal thickness, highlighting its potential in the early detection of diseases like type 2 diabetes ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...

The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...

Dancing the Blues Away' Seen in Brain Imaging in People With Parkinson's Disease, New Study Finds Dec. 18, 2024 — Dancing lowers the depression associated with Parkinson's disease, and the ...

AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment ...

A few years after Patrick Morrissey, 53, learned he had early onset Parkinson's disease, a group of friends came to him with ...

Parkinson's disease is a progressive neurodegenerative disorder, which is characterized by motor symptoms such as tremor, rigidity, slowness of movement and problems with gait. Motor symptoms are ...